The Asia Pacific drug delivery systems market is expected to reach US$ 441,337.0 Mn in 2027 from US$ 212,012.7 Mn in 2018. The market is estimated to grow with a CAGR of 8.6% from 2019-2027.
The growth of the drug delivery systems market is primarily attributed to the rapid technological advancements in diabetes care devices and increasing rate of obesity. However, increasing reuse of pen needles is likely to pose a negative impact on the market growth. On the other hand, growing medical tourism in the emerging nations is likely to have a positive impact on the growth of the Asia Pacific drug delivery systems market in the coming years.
The advancement in the field of the healthcare industry is driving to the players for more research and developments for the drug delivery systems for the administration purpose required during various medical conditions. The pen needles used in various injection pens have evolved gradually in terms of material, performance, dimensions and safety factors such as sterility and safety packaging. Various manufacturers are coming up with innovative products to sustain in the highly fragmented drug delivery systems market, in the region. Moreover, the easy regulatory approvals in the Asian countries has led to mid-sized companies enter the market and compete with the local and established players. For instance, in May 2018, Hindustan Syringes and Medical Devices (HMD), one of the leading manufacturers of disposable syringes introduced “Dispovan” insulin pen needle which is the first made-in-India disposable pen needle that is technologically efficient and affordable than that of the currently available products in the market. Development of pen needles with precise lubrication to reduce the pain sensation has been another focus of manufacturers during the research. Thus, owing to the above mentioned factors the market for drug delivery systems anticipated to grow rapidly in the forecast period, in the region.
In 2018, the oral segment held a largest market share of 50.2% of the drug delivery systems market, by route of administration. The oral segment is expected to dominate its market share in 2027 owing to ease of drug administration, high degree of flexibility on dosages and cost effectiveness.
In 2018, the hospitals and clinics held a largest market share of 56.0% of the drug delivery systems market, by application. This segment is also expected to dominate the market in 2027 owing to the large number of patient population visiting hospitals and clinics. Also hospitals provide diagnosis and treatment for various medical conditions.
In 2018, the hospitals pharmacies held a largest market share of 68.7% of the drug delivery systems market, by distribution channel. This segment is also expected to dominate the market in 2027 as hospital pharmacies provide larger range of medications, including more specialized and investigational medications.
Some of the major primary and secondary sources for drug delivery systems included in the report are, Chinese Academy of Sciences (CAS), Centers for Diabetes and Endocrinology (CDE), China Initiative for Diabetes Excellence (CIDE), Vision Health Initiative (VHI) and others.
Reasons to Buy:
The growth of the drug delivery systems market is primarily attributed to the rapid technological advancements in diabetes care devices and increasing rate of obesity. However, increasing reuse of pen needles is likely to pose a negative impact on the market growth. On the other hand, growing medical tourism in the emerging nations is likely to have a positive impact on the growth of the Asia Pacific drug delivery systems market in the coming years.
The advancement in the field of the healthcare industry is driving to the players for more research and developments for the drug delivery systems for the administration purpose required during various medical conditions. The pen needles used in various injection pens have evolved gradually in terms of material, performance, dimensions and safety factors such as sterility and safety packaging. Various manufacturers are coming up with innovative products to sustain in the highly fragmented drug delivery systems market, in the region. Moreover, the easy regulatory approvals in the Asian countries has led to mid-sized companies enter the market and compete with the local and established players. For instance, in May 2018, Hindustan Syringes and Medical Devices (HMD), one of the leading manufacturers of disposable syringes introduced “Dispovan” insulin pen needle which is the first made-in-India disposable pen needle that is technologically efficient and affordable than that of the currently available products in the market. Development of pen needles with precise lubrication to reduce the pain sensation has been another focus of manufacturers during the research. Thus, owing to the above mentioned factors the market for drug delivery systems anticipated to grow rapidly in the forecast period, in the region.
In 2018, the oral segment held a largest market share of 50.2% of the drug delivery systems market, by route of administration. The oral segment is expected to dominate its market share in 2027 owing to ease of drug administration, high degree of flexibility on dosages and cost effectiveness.
In 2018, the hospitals and clinics held a largest market share of 56.0% of the drug delivery systems market, by application. This segment is also expected to dominate the market in 2027 owing to the large number of patient population visiting hospitals and clinics. Also hospitals provide diagnosis and treatment for various medical conditions.
In 2018, the hospitals pharmacies held a largest market share of 68.7% of the drug delivery systems market, by distribution channel. This segment is also expected to dominate the market in 2027 as hospital pharmacies provide larger range of medications, including more specialized and investigational medications.
Some of the major primary and secondary sources for drug delivery systems included in the report are, Chinese Academy of Sciences (CAS), Centers for Diabetes and Endocrinology (CDE), China Initiative for Diabetes Excellence (CIDE), Vision Health Initiative (VHI) and others.
Reasons to Buy:
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the drug delivery systems market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific drug delivery systems market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution
Table of Contents
1. Introduction
3. Asia Pacific Drug Delivery Systems Market - Market Landscape
4. Asia Pacific Drug Delivery Systems Market - Key Market Dynamics
5. Drug Delivery Systems Market - Asia Pacific Analysis
6. Asia Pacific Drug Delivery Systems Market Analysis - By Route Of Administration
7. Asia Pacific Drug Delivery Systems Market Analysis - By Application
8. Asia Pacific Drug Delivery Systems Market Analysis - By Distribution Channel
9. Asia Pacific Drug Delivery Systems Market Revenue And Forecasts To 2027
10. Drug Delivery Systems Market - Industry Landscape
11. Drug Delivery Systems Market-Key Company Profiles
12. Appendix
13. Glossary of Terms, Drug delivery systems market
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- BD
- 3M
- Novo Nordisk A/S
- BD
- Novo Nordisk A/S
- Boston Scientific Corporation
- Bausch Health Companies Inc.
- Baxter
- Boehringer Ingelheim
- Novartis AG
- GlaxoSmithKline plc.
- Johnson & Johnson Services, Inc.